Shimadzu, Phenomenome, Capital Bio, BioMachines, AlgoNomics, Mat Biopharma, Strategic Diagnostics, Syngene | GenomeWeb

Shimadzu to Collaborate with Phenomenome in Biomarker Discovery, Proteomic Studies

Shimadzu and Phenomenome Discoveries have agreed to collaborate exclusively to develop tools for biomarker discovery and global profiling studies, including proteomic studies, the companies said this week.

A year ago, Shimadzu and Phenomenome inked a deal that allowed researchers to use Phenomenome's informatics platform to visualize and interpret mass spectrometry data generated by Shimadzu technology for metabolomics research.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.